USFDA completes inspection of Nagpur facility, no observation issued, reveals Drug firm Lupin
- Country:
- India
New Delhi, Sep 14 (PTI) Drug firm Lupin Friday said the US health regulator has completed an inspection of its Nagpur facility in Maharashtra without any observation.
The product-specific pre-approval inspection by USFDA concluded without any observation, Lupin said in a BSE filing.
Shares of Lupin were trading at Rs 972.80 apiece, up 1.72 percent, from the previous close on BSE.
Google News